CN105939724B - 用于治疗和预防转移癌的药物组合物和方法 - Google Patents

用于治疗和预防转移癌的药物组合物和方法 Download PDF

Info

Publication number
CN105939724B
CN105939724B CN201480074295.5A CN201480074295A CN105939724B CN 105939724 B CN105939724 B CN 105939724B CN 201480074295 A CN201480074295 A CN 201480074295A CN 105939724 B CN105939724 B CN 105939724B
Authority
CN
China
Prior art keywords
cancer
peptide
amino acid
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480074295.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105939724A (zh
Inventor
Y·德瓦里
U·桑德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune System Key Ltd
Original Assignee
Immune System Key Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune System Key Ltd filed Critical Immune System Key Ltd
Publication of CN105939724A publication Critical patent/CN105939724A/zh
Application granted granted Critical
Publication of CN105939724B publication Critical patent/CN105939724B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201480074295.5A 2013-12-05 2014-12-04 用于治疗和预防转移癌的药物组合物和方法 Active CN105939724B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912156P 2013-12-05 2013-12-05
US61/912,156 2013-12-05
PCT/IL2014/051058 WO2015083167A1 (en) 2013-12-05 2014-12-04 Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer

Publications (2)

Publication Number Publication Date
CN105939724A CN105939724A (zh) 2016-09-14
CN105939724B true CN105939724B (zh) 2020-01-14

Family

ID=52292983

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480074295.5A Active CN105939724B (zh) 2013-12-05 2014-12-04 用于治疗和预防转移癌的药物组合物和方法

Country Status (11)

Country Link
US (1) US9878015B2 (enExample)
EP (1) EP3076988B1 (enExample)
JP (1) JP6609556B2 (enExample)
KR (1) KR102384795B1 (enExample)
CN (1) CN105939724B (enExample)
AU (1) AU2014358671B2 (enExample)
CA (1) CA2931023C (enExample)
DK (1) DK3076988T3 (enExample)
ES (1) ES2742856T3 (enExample)
IL (1) IL245998B (enExample)
WO (1) WO2015083167A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018130764A (ru) * 2016-02-04 2020-03-04 Имьюн Систем Ки Лтд. Стресс эндоплазматического ретикулума как прогностический инструмент в терапии рака и комбинированная терапия для лечения рака
KR20250009999A (ko) * 2022-05-27 2025-01-20 주식회사 진큐어 신규 펩타이드 및 그의 용도
WO2024228200A1 (en) * 2023-05-03 2024-11-07 Immune System Key Ltd. Cyclic d-peptides, derivatives, compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046239A3 (en) * 2004-10-25 2006-07-13 Immune System Key Ltd A thymus-specific protein
WO2007122622A1 (en) * 2006-04-24 2007-11-01 Immune System Key Ltd. Method of treatment of a disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007091240A2 (en) 2006-02-06 2007-08-16 Immune System Key Ltd. Treatment of immunological diseases
US20100204097A1 (en) 2006-12-18 2010-08-12 Immune System Key Ltd. Therapeutic methods using a thymus peptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046239A3 (en) * 2004-10-25 2006-07-13 Immune System Key Ltd A thymus-specific protein
WO2007122622A1 (en) * 2006-04-24 2007-11-01 Immune System Key Ltd. Method of treatment of a disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Uziel Sandler et al.NEROFE™- A novel human hormone-peptide with anti-cancer activity.《Journal of Experimental Therapeutics and Oncology》.2010,第327-339页. *

Also Published As

Publication number Publication date
CA2931023A1 (en) 2015-06-11
IL245998A0 (en) 2016-07-31
US9878015B2 (en) 2018-01-30
EP3076988A1 (en) 2016-10-12
DK3076988T3 (da) 2019-09-16
KR102384795B1 (ko) 2022-04-08
AU2014358671B2 (en) 2019-09-12
AU2014358671A1 (en) 2016-06-02
CN105939724A (zh) 2016-09-14
EP3076988B1 (en) 2019-06-05
IL245998B (en) 2019-12-31
KR20160085361A (ko) 2016-07-15
JP6609556B2 (ja) 2019-11-20
WO2015083167A1 (en) 2015-06-11
JP2017505755A (ja) 2017-02-23
US20160303200A1 (en) 2016-10-20
CA2931023C (en) 2023-12-19
ES2742856T3 (es) 2020-02-17

Similar Documents

Publication Publication Date Title
ES2234818T3 (es) Procedimiento para tratar canceres que expresan el factor de crecimiento endotelial d.
JP6921755B2 (ja) 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物
US20240108686A1 (en) DPEP-1 Binding Compositions and Methods of Use
WO2007143023A1 (en) Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
US8883738B2 (en) Use of a peptide fragment of CD44v6 in the treatment of ophthalmic diseases
CN105939724B (zh) 用于治疗和预防转移癌的药物组合物和方法
US20150071855A1 (en) Egfl7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis
EP1448593B1 (en) Alpha-fetoprotein peptides and uses thereof
EP4351613A1 (en) Methods, compositions and uses for targeting sema7a in the diagnosis and treatment of health conditions
KR20190064562A (ko) Mena 단백질 이소형 키나제를 표적화하는 항암 요법을 위한 방법 및 조성물
KR20230005314A (ko) 수포성 표피박리증의 치료에 사용하기 위한 귀소 펩티드 유도 데코린 접합체
HK1229242B (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
HK1229242A1 (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
US20110269692A1 (en) Alpha-fetoprotein peptides and uses thereof
WO2025068426A1 (en) Treatment of cancers associated with beta-catenin
Isorna et al. Role of Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: New Targets for Cancer Treatment
KR20230120585A (ko) c-MET의 에피토프 및 HIF1α의 에피토프를 포함하는 암 백신 및 이의 용도
KR20230120542A (ko) c-MET의 에피토프 및 HIF1α의 에피토프를 포함하는 암 백신 및 이의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant